CompletedNCT02911324
Nabilone With or Without Exposure Therapy for OCD
About this title
Read the official source — NCT02911324Medication studyAges 18–60United States
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateSeptember 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT02911324
- Official title
Show the full official title
Cannabinoid Medication for Adults With Obsessive-Compulsive Disorder (OCD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Nabilone.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
